CN105980381A - 取代的尿嘧啶及其用途 - Google Patents
取代的尿嘧啶及其用途 Download PDFInfo
- Publication number
- CN105980381A CN105980381A CN201480072711.8A CN201480072711A CN105980381A CN 105980381 A CN105980381 A CN 105980381A CN 201480072711 A CN201480072711 A CN 201480072711A CN 105980381 A CN105980381 A CN 105980381A
- Authority
- CN
- China
- Prior art keywords
- represent hydrogen
- alkyl
- mmol
- methyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C1c2cc(*)cc(*)c2*C1 Chemical compound *C1c2cc(*)cc(*)c2*C1 0.000 description 21
- YVKIYJMGWDSMAN-SFQUDFHCSA-N CC(/C(/C(O)=O)=C\N(C(NCc1c(C(F)(F)F)c(F)ccc1)=O)c(cc1)ccc1N(CCO1)C1=O)=O Chemical compound CC(/C(/C(O)=O)=C\N(C(NCc1c(C(F)(F)F)c(F)ccc1)=O)c(cc1)ccc1N(CCO1)C1=O)=O YVKIYJMGWDSMAN-SFQUDFHCSA-N 0.000 description 1
- FRPCCJCCCAOXMA-UHFFFAOYSA-N CC(C(CC=C)(c1cccc2c1CCC2)N)=C Chemical compound CC(C(CC=C)(c1cccc2c1CCC2)N)=C FRPCCJCCCAOXMA-UHFFFAOYSA-N 0.000 description 1
- LMLZCNFUOOJMNQ-UHFFFAOYSA-N CCOC(C(C(N(Cc1cccc(Cl)c1Cl)C1O)=O)=CN1c(cc1)ccc1-c1nnc(N)[o]1)=O Chemical compound CCOC(C(C(N(Cc1cccc(Cl)c1Cl)C1O)=O)=CN1c(cc1)ccc1-c1nnc(N)[o]1)=O LMLZCNFUOOJMNQ-UHFFFAOYSA-N 0.000 description 1
- ALAHOTOAEIUEMP-HXRHHXETSA-N CCOC(C(C(N1)=O)=CN(/C(/C=C(\C(C)N(CCN2)C2=O)/F)=C/CF)C1=O)=O Chemical compound CCOC(C(C(N1)=O)=CN(/C(/C=C(\C(C)N(CCN2)C2=O)/F)=C/CF)C1=O)=O ALAHOTOAEIUEMP-HXRHHXETSA-N 0.000 description 1
- DWIUREOPONBGIJ-UHFFFAOYSA-N CCOC(C(C(N1)=O)=CN(c(cc2)ccc2N(C)CC[O]=C=O)C1=O)O Chemical compound CCOC(C(C(N1)=O)=CN(c(cc2)ccc2N(C)CC[O]=C=O)C1=O)O DWIUREOPONBGIJ-UHFFFAOYSA-N 0.000 description 1
- QJQJFNMDGOBILB-UHFFFAOYSA-N CCOC(C(C(N1)=O)=CN(c(cc2)ccc2OCC(N)=O)C1=O)=O Chemical compound CCOC(C(C(N1)=O)=CN(c(cc2)ccc2OCC(N)=O)C1=O)=O QJQJFNMDGOBILB-UHFFFAOYSA-N 0.000 description 1
- MIHRISLNJUOXJR-UHFFFAOYSA-N CCOC(C(C(N1)=O)=CN(c(cc2Cl)cc(Cl)c2N(CCO2)C2=O)C1=O)=O Chemical compound CCOC(C(C(N1)=O)=CN(c(cc2Cl)cc(Cl)c2N(CCO2)C2=O)C1=O)=O MIHRISLNJUOXJR-UHFFFAOYSA-N 0.000 description 1
- YHKWEUXEKYPDCT-UHFFFAOYSA-N CCOC(C(C(N1Cc(cccc2Cl)c2Cl)=O)=CN(c(cc2F)ccc2N(CCN2)C2O)C1=O)=O Chemical compound CCOC(C(C(N1Cc(cccc2Cl)c2Cl)=O)=CN(c(cc2F)ccc2N(CCN2)C2O)C1=O)=O YHKWEUXEKYPDCT-UHFFFAOYSA-N 0.000 description 1
- TWUKIOHPNAIIRA-UHFFFAOYSA-N CCOC(C(C(N1Cc2cccc([N+](O)=O)c2C)=O)=CN(c(cc2)ccc2C(CCNS(C)(=O)=O)=C)C1=O)=O Chemical compound CCOC(C(C(N1Cc2cccc([N+](O)=O)c2C)=O)=CN(c(cc2)ccc2C(CCNS(C)(=O)=O)=C)C1=O)=O TWUKIOHPNAIIRA-UHFFFAOYSA-N 0.000 description 1
- WBWLRSQSVSAIQG-UHFFFAOYSA-N Cc(c(CN(C(C(CCc(cc1OC)ccc1OC)C=C1C(O)O)=O)C1=O)ccc1)c1Cl Chemical compound Cc(c(CN(C(C(CCc(cc1OC)ccc1OC)C=C1C(O)O)=O)C1=O)ccc1)c1Cl WBWLRSQSVSAIQG-UHFFFAOYSA-N 0.000 description 1
- VEAACGXXNZTXGF-UHFFFAOYSA-N Cc1c(CCC2NC(N)=O)c2ccc1 Chemical compound Cc1c(CCC2NC(N)=O)c2ccc1 VEAACGXXNZTXGF-UHFFFAOYSA-N 0.000 description 1
- QUDAKRQSDLXKER-UHFFFAOYSA-N O=C(NCC1)N1c(ccc([NH2+][U])c1)c1F Chemical compound O=C(NCC1)N1c(ccc([NH2+][U])c1)c1F QUDAKRQSDLXKER-UHFFFAOYSA-N 0.000 description 1
- SPZYIUUUWUKXRU-UHFFFAOYSA-N OC(C(C(N1Cc2c(C(F)(F)F)c(F)ccc2)=O)=CN(c(cc2F)cc(F)c2N(CCN2)C2=O)C1=O)=O Chemical compound OC(C(C(N1Cc2c(C(F)(F)F)c(F)ccc2)=O)=CN(c(cc2F)cc(F)c2N(CCN2)C2=O)C1=O)=O SPZYIUUUWUKXRU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192181.9 | 2013-11-08 | ||
| EP13192181 | 2013-11-08 | ||
| PCT/EP2014/073760 WO2015067630A1 (de) | 2013-11-08 | 2014-11-05 | Substituierte uracile und ihre verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105980381A true CN105980381A (zh) | 2016-09-28 |
Family
ID=49582562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480072711.8A Pending CN105980381A (zh) | 2013-11-08 | 2014-11-05 | 取代的尿嘧啶及其用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9751843B2 (enExample) |
| EP (1) | EP3066098A1 (enExample) |
| JP (1) | JP2016536362A (enExample) |
| CN (1) | CN105980381A (enExample) |
| CA (1) | CA2929753A1 (enExample) |
| WO (1) | WO2015067630A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021000933A1 (zh) * | 2019-07-03 | 2021-01-07 | 南京明德新药研发有限公司 | 作为糜酶抑制剂的嘧啶酮类化合物及其应用 |
| CN114671878A (zh) * | 2020-12-25 | 2022-06-28 | 广东东阳光药业有限公司 | 取代的含氮双环化合物及其用途 |
| CN114671856A (zh) * | 2020-12-25 | 2022-06-28 | 广东东阳光药业有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| WO2022135514A1 (zh) * | 2020-12-25 | 2022-06-30 | 广东东阳光药业有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| CN117582909A (zh) * | 2024-01-19 | 2024-02-23 | 天津凯莱英医药科技发展有限公司 | 一种连续生产5-单硝酸异山梨酯的系统和方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3338780A1 (de) | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023260A (en) * | 1989-04-13 | 1991-06-11 | Bayer Aktiengesellschaft | Substituted uracils, processes for their preparation and their use against parasitic protozoa |
| CN1871029A (zh) * | 2003-08-22 | 2006-11-29 | 帝人制药株式会社 | 含有类糜蛋白酶抑制剂作为有效成分的药物 |
| CN101505752A (zh) * | 2006-06-23 | 2009-08-12 | 史密丝克莱恩比彻姆公司 | 脯氨酸羟化酶抑制剂 |
| WO2009156182A2 (de) * | 2008-06-25 | 2009-12-30 | Resprotect Gmbh | Uracilderivate und deren verwendung |
| WO2013074633A1 (en) * | 2011-11-14 | 2013-05-23 | Cephalon, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4096173A (en) | 1977-03-28 | 1978-06-20 | Eli Lilly And Company | Chlorinated 1-aminoindane N-methyl transferase inhibitors |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| NZ512891A (en) | 1998-12-22 | 2003-01-31 | Janssen Pharmaceutica Nv | S-oxide lipid lowering compounds |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| US7160912B2 (en) | 2000-12-26 | 2007-01-09 | Dr.Reddy's Laboratories Ltd. | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them |
| DE10102322A1 (de) | 2001-01-19 | 2002-07-25 | Merck Patent Gmbh | Phenylderivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| AU2003290735A1 (en) | 2002-12-06 | 2004-06-30 | Eli Lilly And Company | Inhibitors of monoamine uptake |
| DE10342570A1 (de) | 2003-09-15 | 2005-04-14 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon |
| AR046845A1 (es) | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| UY29896A1 (es) | 2005-11-04 | 2007-06-29 | Astrazeneca Ab | Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
| GB0614552D0 (en) | 2006-07-21 | 2006-08-30 | Syngenta Ltd | Chemical Compounds |
| GB0622472D0 (en) | 2006-11-10 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel heterocyclic derivatives |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| US7884244B2 (en) | 2007-04-12 | 2011-02-08 | Allergan, Inc. | Therapeutic fluoroethylcyano guanidines |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009064835A1 (en) | 2007-11-16 | 2009-05-22 | Incyte Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| LT2318006T (lt) | 2008-08-15 | 2017-01-10 | Nivalis Therapeutics, Inc. | Nauji s-nitrozoglutationo reduktazės pirolo inhibitoriai, kaip terapiniai agentai |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
-
2014
- 2014-11-05 CA CA2929753A patent/CA2929753A1/en not_active Abandoned
- 2014-11-05 US US15/034,499 patent/US9751843B2/en active Active
- 2014-11-05 WO PCT/EP2014/073760 patent/WO2015067630A1/de not_active Ceased
- 2014-11-05 EP EP14799129.3A patent/EP3066098A1/de not_active Withdrawn
- 2014-11-05 CN CN201480072711.8A patent/CN105980381A/zh active Pending
- 2014-11-05 JP JP2016551029A patent/JP2016536362A/ja not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023260A (en) * | 1989-04-13 | 1991-06-11 | Bayer Aktiengesellschaft | Substituted uracils, processes for their preparation and their use against parasitic protozoa |
| CN1871029A (zh) * | 2003-08-22 | 2006-11-29 | 帝人制药株式会社 | 含有类糜蛋白酶抑制剂作为有效成分的药物 |
| CN101505752A (zh) * | 2006-06-23 | 2009-08-12 | 史密丝克莱恩比彻姆公司 | 脯氨酸羟化酶抑制剂 |
| WO2009156182A2 (de) * | 2008-06-25 | 2009-12-30 | Resprotect Gmbh | Uracilderivate und deren verwendung |
| WO2013074633A1 (en) * | 2011-11-14 | 2013-05-23 | Cephalon, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| STEVEN J.TAYLOR ET AL.: "Discovery of potent, Selective Chymase Inhibitors via Fragemnt Linking Strategies", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021000933A1 (zh) * | 2019-07-03 | 2021-01-07 | 南京明德新药研发有限公司 | 作为糜酶抑制剂的嘧啶酮类化合物及其应用 |
| CN113811530A (zh) * | 2019-07-03 | 2021-12-17 | 南京明德新药研发有限公司 | 作为糜酶抑制剂的嘧啶酮类化合物及其应用 |
| CN113811530B (zh) * | 2019-07-03 | 2022-07-19 | 南京明德新药研发有限公司 | 作为糜酶抑制剂的嘧啶酮类化合物及其应用 |
| CN114685472A (zh) * | 2020-12-25 | 2022-07-01 | 广东东阳光药业有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| WO2022135534A1 (zh) * | 2020-12-25 | 2022-06-30 | 广东东阳光药业有限公司 | 取代的含氮双环化合物及其用途 |
| WO2022135514A1 (zh) * | 2020-12-25 | 2022-06-30 | 广东东阳光药业有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| CN114671856A (zh) * | 2020-12-25 | 2022-06-28 | 广东东阳光药业有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| CN114671878A (zh) * | 2020-12-25 | 2022-06-28 | 广东东阳光药业有限公司 | 取代的含氮双环化合物及其用途 |
| CN114671878B (zh) * | 2020-12-25 | 2023-08-04 | 广东东阳光药业有限公司 | 取代的含氮双环化合物及其用途 |
| CN114671856B (zh) * | 2020-12-25 | 2023-10-20 | 广东东阳光药业股份有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| CN114685472B (zh) * | 2020-12-25 | 2024-04-26 | 广东东阳光药业股份有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| CN117582909A (zh) * | 2024-01-19 | 2024-02-23 | 天津凯莱英医药科技发展有限公司 | 一种连续生产5-单硝酸异山梨酯的系统和方法 |
| CN117582909B (zh) * | 2024-01-19 | 2024-04-02 | 天津凯莱英医药科技发展有限公司 | 一种连续生产5-单硝酸异山梨酯的系统和方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US9751843B2 (en) | 2017-09-05 |
| CA2929753A1 (en) | 2015-05-14 |
| WO2015067630A1 (de) | 2015-05-14 |
| EP3066098A1 (de) | 2016-09-14 |
| JP2016536362A (ja) | 2016-11-24 |
| US20160297771A1 (en) | 2016-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI635085B (zh) | 經雙環取代之尿嘧啶類及其用途 | |
| TWI794297B (zh) | 化合物用於製備與第二抗-呼吸道融合性病毒試劑組合使用以治療呼吸道細胞融合病毒感染的藥物之用途及醫藥組合物 | |
| US9695131B2 (en) | Substituted uracils as chymase inhibitors | |
| CN112469412A (zh) | 取代的二氢吡唑并吡嗪甲酰胺衍生物 | |
| US9751843B2 (en) | Substituted uracils and use thereof | |
| CN102666531A (zh) | 杂环-取代的2-乙酰氨基-5-芳基-1,2,4-三唑酮和其应用 | |
| CN105899500A (zh) | 取代的1，2，4-三嗪-3，5-二酮及其作为类糜蛋白酶抑制剂的用途 | |
| CN107108638A (zh) | 哌啶基吡唑并嘧啶酮及其用途 | |
| HK1224663A1 (zh) | 取代的尿嘧啶及其用途 | |
| CN103119027A (zh) | 取代的苯乙酰胺和苯丙酰胺及其用途 | |
| HK1202873B (en) | Bicyclically substituted uracils and the use thereof | |
| CA3205277A1 (en) | Erap inhibitors | |
| HK40042113A (en) | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1224663 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160928 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1224663 Country of ref document: HK |